NO7’ BEAUTY COMPANY ANNOUNCES RESULTS FROM A LONG-TERM STUDY OF THE BENEFITS OF FUTURE RENEW SERUM , FORMULATED WITH A BREAKTHROUGH SKINCARE INNOVATION AND PROVEN TO REVERSE VISIBLE SIGNS OF SUN DAMAGE
Combatting years of incidental sun exposure, Future Renew Damage Reversal Serum contains a world-first peptide technology and is clinically proven to reduce visible signs of sun damage, the biggest cause of visible signs of skin ageing
New York, N.Y., August 13, 2024 -- No7 Beauty, the #1 skincare brand in the UK, has been making beauty history for 100 years and continues to break new ground in the US market. Sun is responsible for up to 80% of visible signs of aging to the skin and one year after launching Future Renew, the brand’s biggest launch and scientific innovation to date, the Future Renew Damage Reversal Serum is now clinically proven to deliver ongoing improvements to visible signs of sun damage with regular use.*. The visible signs of photodamage include pigmentation, firmness, fine lines and wrinkles.
The Future Renew serum containing a world-first peptide technology, one of the biggest cosmetic science breakthroughs in a generation, was tested in clinical trial over 12 months, and the Future Renew range is the most extensively and diversely tested product range in No7 Beauty’s history, with more than 5,100 people across 52 trials. The most recent results related to sun damage include:
- 97% of women had a reversal in the appearance of multiple signs of damage in a clinical split-face trial carried out over 48 weeks
- 67% of women saw a reversal in the appearance of pigmentation and dark spots in home use testing
Dr. Mike Bell, Head of Science Research, No7 Beauty comments: “Cumulative studies are rarely published which means that little is known about the long-term benefits of cosmetic products. This study is therefore particularly illuminating because it provides compelling evidence that the No7 Future Renew serum delivers incrementally proven results through long-term use, delivering ongoing improvements in key signs of damage over 12 months of use. Those key signs of damage include lines and wrinkles, uneven skin tone, dryness, dullness and lack of firmness.”
The discovery of the new super peptide blend in the Future Renew range was the result of a 15-year collaboration between No7 Beauty and the University of Manchester in the UK. It was developed using cutting-edge R&D across several fields of science and technology, with scientific methods and approaches that are more akin to medical research and rarely seen in cosmetic product development.
Commenting on the clinical trial, Dr. Hope Mitchell, a leading dermatologist and fan of No7 Beauty, says: “I was an early adopter of Future Renew and am thrilled to learn of the extended study’s findings. I’ve recommended this product to countless patients as sun damage is one of the most common skin concerns. In this era of skincare misinformation online, it’s invaluable to now have real data to illustrate how effective the formulation is in targeting the loss of firmness, uneven skin tone and wrinkles caused by sun exposure. Future Renew, when combined with a daily skincare regimen of a daily cleanser and sunscreen, is my go-to recommendation for visible damage reversal.”
The No7 Future Renew range took the world by storm when it launched in April 2023 and has since become a favorite of celebrities and dermatologists alike, including actor and filmmaker Elizabeth Banks, a longtime fan of the brand and official face of the Future Renew collection. The No7 Future Renew range was the UK’s biggest ever beauty launch with over 500,000 units sold in the first four weeks. Since then, one product has continued to sell every seven seconds in the UK.
The No7 Future Renew range is available nationwide in stores and online at Walgreens, Walmart, Target, and Ulta, and online at Amazon and us.no7beauty.comus.no7beauty.com.
THE FUTURE RENEW RANGE
No7 FUTURE RENEW DAMAGE REVERSAL SERUM 0.84 fl oz - $39.99
No7 Future Renew Serum is proven in home user testing to reverse visible signs of sun damage. The serum contains the super peptide blend, as well as niacinamide, hyaluronic acid, vitamin C, mulberry and hydrolysed rice proteins.
No7 FUTURE RENEW DAMAGE REVERSAL SPF 25 DAY CREAM 1.69 fl oz - $39.99
No7 Future Renew Day Cream is proven to protect against UV, targeting visible signs of sun damage, such as the feeling of dryness and loss of elasticity. It contains SPF 25 for sun damage protection, No7’s super peptide blend, an antioxidant blend, niacinamide, hyaluronic acid, vitamin C and rice proteins. It intensely moisturises the skin for up to 72 hours, and within 1 week of use, users reported brighter, healthier, more supple skin.
No7 FUTURE RENEW DAMAGE REVERSAL NIGHT CREAM 1.69 fl oz - $39.99
No7 Future Renew Night Cream is expertly formulated to support skin's natural self-repair process while sleeping and reverse visible signs of skin damage. It contains the super peptide blend, along with other key nourishing ingredients including shea butter, niacinamide and hyaluronic acid. This night cream helps reverse the appearance of uneven tone and texture, dry skin and lost elasticity. It deeply moisturizes for up to 72 hours, and delivers instant results with more nourished, softer and smoother skin. In as little as one week, users reported their skin felt supple and texture more even.
No7 FUTURE RENEW DAMAGE REVERSAL EYE SERUM 0.5 fl oz - $29.99
The skin around the eyes is thinner and more delicate than elsewhere on the face, meaning it is more susceptible to damage. Expertly developed for the delicate eye area, No7 Future Renew Eye Serum reverses visible signs of skin damage in 8 weeks. In addition to No7's super peptide blend, the eye serum also contains hyaluronic acid, niacinamide, vitamin C, an antioxidant blend and rice proteins. In one week, the appearance of fine lines is reduced, and after four weeks, the appearance of wrinkles and puffiness is reduced, and skin tone looks more even.
For further information, quotes or imagery, please contact:
No7Beauty@ogilvy.com
- Ends –
*Flament F et al: Clinical, Cosmetic and Investigational Dermatology 2013:6 221–232